Liver transplantation in HCV/HIV positive patients

Table 1 Inclusion criteria for liver transplantation

NIH sponsored study in the USA[94]	1. No AIDS-related opportunistic infections
	2. CD4 counts should be > 100/mL for those without a history of opportunistic infection and > 200/mL for those with a history of opportunistic infection.
	3. HIV-RNA should be undetectable. In the event that an undetectable HIV viral load is not achievable as a result of drug-induced hepatotoxic, an HIV clinician should predict the ability to control the HIV virus post-transplantation.
Spanish criteria[41]	1. No opportunistic infections
	2. CD4 counts > 100/mL
	3. HIV-RNA should be undetectable or suppressible with antiretroviral therapy.
O’Grady[95]	1. Absence of AIDS-defining illness after immune reconstitution
	2. CD4 counts should be > 200/mL or > 100/mL in the presence of portal hypertension.
	3. Absence of HIV viremia
	4. Antiretroviral therapeutic options available if the HIV disease reactivates

AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus.

Table 2 Survival, hepatitis C virus recurrence, and therapy in hepatitis C virus/human immunodeficiency virus co-infected liver transplant patients

References	Institution	Years	n	Genotypes	Time to recurrence (mo)	IFN and RBV doses	Time to therapy (mo)	SVR (%)	FCH (n)	Death (n)	Follow up (mo)
Prachialis 2001[58], Norris 2004[56]	King’s College	95-03	7	NA	5	From 2 wk: IFN, 3 MU tiw and RBV, after 3 wk: Peg- IFN 180 μg/wk	0.5 (n = 2), 6 m (n = 1)	0	2	5	12
Rafecas 2004[51]	Hospital Universitari de Bellvitge	02-03	4	4, 1b, 1b, 1a	7	NA	5 (n = 3)	0	0	0	17
Moreno 2005[55]	Hospital Ramon (Madrid)	02-03	4	NA	1-6	NA	1-6	0	1	1	14-18
Radecke 2005[57]	University Hospital Essen	98-01	4	NA	3-8	NA	NA	NA	1	2	10-61
Vogel 2005[48]	Bonn University	97-04	4	1a (n = 2), 2a/2c, 3a	1-8	NA	5-15	50	0	0	NA
Neff 2003[33], Fung 2004[71], de Vera 2006[35]	Thomas E Starzl Transplantation Institute	97-05	27	1 (n = 16), 2 (n = 2), 3 (n = 1)	6	IFN and Peg -IFN, RBV 800 mg/d	2-50	27	6	14	27+-5
Castells 2007[53]	Hospital Universitari Vall d’Hebro'n (Barcelona)	02-05	9	1 (n = 7), 3 (n = 2)	3+-3	Peg-IFN 1.5 μg/kg, RBV 800-1000 mg/d	NA	14	0	1	15+-13
Schreibman 2007[45]	University of Miami	99-06	8	NA	NA	NA	NA	25	0	2	6-74
Vennarecci 2007[52]	Regina Elena Cancer Institute (Rome)	02-06	10	NA	NA	NA	NA	10	3	6	5-46
Wojcik 2007[88]	Medical University of Lodz (Poland)	97-06	4	1a (n = 2), 2a, 3a	1-3	Peg-IFN 180 μg/wk, RBV 200-1000 mg/d	1-3	100	0	0	21-54
Duclos-Vallee 2005[50], 2008[42]	Paul Brousse	99-05	35	1 (n = 20), 2 (n = 1), 3 (n = 9), 4 (n = 4)	0-3	Peg-IFN 50-180 μg/wk, and RBV 400-800 mg/d	0-3	16	3	13	44+-83
Stock 2003[43], Roland 2008[96]	University of California, San Francisco	00-03	6	NA	1-11	NA	1-11	NA	2	4	NA
Testillano 2009[97]	Hospital de Cruces (Vizcaya)	01-07	12	1 (n = 8), 3 (n = 4)	NA	NA	NA	50	2	4	NA
Hughes 2010[98]	Emory University School of Medicine	NA	5	1	2-12	Peg-IFN 135-180 μg/wk, and RBV 600 mg/d	2-12	40	2	2	6-48
Di Benedetto 2008[54], 2010[99]	University of Modena and Reggio Emilia	03-	13	1 (n = 3), 3a (n = 7), 4 (n = 3)	2-16	Peg-IFN 50-180 μg/wk, and RBV 400-800 mg/d	NA	0	2	4	1-14

HCV: hepatitis C; IFN: interferon; Peg-IFN: pegylated interferon; RBV: ribavirin; SVR: sustained virological response; NA: not available; FCH: fibrosing cholestatic hepatitis.